D3 Bio Announces Oral Presentation of the Clinical Data of Its Lead Program, D3S-001, at the ESMO Congress 2024

Shanghai, China, September 12, 2024 — D3 Bio, a global biotechnology company that focuses on discovery, development, and registration of innovative cancer drugs, announced that it will present clinical data from its lead oncology program, D3S-001, a second-generation KRAS G12C inhibitor with best-in-class potential, in a mini oral presentation at the ESMO Congress 2024 on September 14, 2024, in Barcelona, Spain.  

The novel molecular mode of action (MoA) of D3S-001 was unveiled and articulated by D3 Bio in a research article published in the September issue of a top peer-reviewed scientific journal Cancer Discovery, concurrently with the clinical data release at ESMO.

Detailed information of the presentation is as the following:

Title:
‍Phase 1/2 Study of D3S-001, a second generation KRAS G12C inhibitor, in advanced/metastatic solid tumors with KRAS G12C mutations

Type:
Mini oral Presentation, Developmental therapeutics

Presentation Date and Time: 
‍Saturday, September 14, 2024, from 15:15 to 15:20 CEST

Location: 
Oviedo Auditorium - Hall 3

PresentationNumber:
615MO

Presenter:
Byoung Chul Cho, MD, PhD, Yonsei Cancer Center, Seoul, Korea

‍

For more information about ESMO Congress 2024, please go to https://www.esmo.org/meeting-calendar/esmo-congress-2024

‍

‍

About D3S-001

D3S-001 is a second-generation KRAS G12C inhibitor designed to enhance KRAS G12C target engagement. In preclinical investigations, D3S-001 has demonstrated high covalent potency, ability to rapidly and completely engage the KRAS G12C target at clinically relevant doses, and CNS penetration properties. D3S-001 is currently in a Phase II global clinical trial in patients with advanced solid tumors harboring a KRAS G12C mutation, including Non-Small Cell Lung Cancer (NSCLC), colorectal cancer (CRC) and other tumor types. For detailed information about D3S-001, please refer to the highlighted Research Article published at the 2024 September issue of Cancer Discovery, titled D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities (Cancer Discovery 1 September 2024; 14 (9): 1675–1698. https://doi.org/10.1158/2159-8290.CD-24-0006).

About D3 Bio

D3 Bio is a global biotechnology company that focuses on the discovery, development, and registration of new medicines in oncology and immunology. The D3 Bio discovery and development platform leverages our proprietary clinical insight and biomarker strategy to guide our discovery and development efforts in creating novel and clinically meaningful new therapies for patients in need. 

D3 Bio is funded by Boyu Capital, Matrix Partners China, HongShan China, Temasek, WuXi AppTec's Corporate Venture Fund, and Medicxi.

‍

Media Contact:

Rui Liu
Head, Corporate Affairs
bd@d3bio.com
Shanghai, China